CMRX vs. BTAI, ETON, PMVP, ONCY, AFMD, QTTB, HOOK, YS, SPRO, and CLSD
Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include BioXcel Therapeutics (BTAI), Eton Pharmaceuticals (ETON), PMV Pharmaceuticals (PMVP), Oncolytics Biotech (ONCY), Affimed (AFMD), Q32 Bio (QTTB), Hookipa Pharma (HOOK), YS Biopharma (YS), Spero Therapeutics (SPRO), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry.
BioXcel Therapeutics (NASDAQ:BTAI) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 35.8% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 10.0% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
BioXcel Therapeutics currently has a consensus price target of $16.71, suggesting a potential upside of 516.76%. Chimerix has a consensus price target of $8.00, suggesting a potential upside of 783.00%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Chimerix is more favorable than BioXcel Therapeutics.
BioXcel Therapeutics has a net margin of -12,974.86% compared to BioXcel Therapeutics' net margin of -25,337.96%. BioXcel Therapeutics' return on equity of -37.93% beat Chimerix's return on equity.
In the previous week, BioXcel Therapeutics had 12 more articles in the media than Chimerix. MarketBeat recorded 14 mentions for BioXcel Therapeutics and 2 mentions for Chimerix. Chimerix's average media sentiment score of 0.58 beat BioXcel Therapeutics' score of 0.30 indicating that BioXcel Therapeutics is being referred to more favorably in the media.
Chimerix has lower revenue, but higher earnings than BioXcel Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Chimerix received 149 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. However, 67.14% of users gave BioXcel Therapeutics an outperform vote while only 64.12% of users gave Chimerix an outperform vote.
BioXcel Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
Summary
Chimerix beats BioXcel Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Chimerix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chimerix Competitors List
Related Companies and Tools
